Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA3087006
Max Phase: Preclinical
Molecular Formula: C36H51N7O5
Molecular Weight: 661.85
Molecule Type: Small molecule
Associated Items:
ID: ALA3087006
Max Phase: Preclinical
Molecular Formula: C36H51N7O5
Molecular Weight: 661.85
Molecule Type: Small molecule
Associated Items:
Canonical SMILES: CC(=O)N[C@H](/C=C/C(=O)N[C@@H](CCCCN)C(=O)N[C@H](/C=C/C(=O)N[C@@H](CCCCN)C(N)=O)Cc1ccccc1)Cc1ccccc1
Standard InChI: InChI=1S/C36H51N7O5/c1-26(44)40-29(24-27-12-4-2-5-13-27)18-20-34(46)43-32(17-9-11-23-38)36(48)41-30(25-28-14-6-3-7-15-28)19-21-33(45)42-31(35(39)47)16-8-10-22-37/h2-7,12-15,18-21,29-32H,8-11,16-17,22-25,37-38H2,1H3,(H2,39,47)(H,40,44)(H,41,48)(H,42,45)(H,43,46)/b20-18+,21-19+/t29-,30-,31+,32+/m1/s1
Standard InChI Key: ZZMNZQHHEHGMBD-UVXIZIQKSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Small molecule | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 661.85 | Molecular Weight (Monoisotopic): 661.3952 | AlogP: 1.29 | #Rotatable Bonds: 22 |
Polar Surface Area: 211.53 | Molecular Species: BASE | HBA: 7 | HBD: 7 |
#RO5 Violations: 2 | HBA (Lipinski): 12 | HBD (Lipinski): 10 | #RO5 Violations (Lipinski): 3 |
CX Acidic pKa: 13.13 | CX Basic pKa: 10.51 | CX LogP: 0.93 | CX LogD: -4.28 |
Aromatic Rings: 2 | Heavy Atoms: 48 | QED Weighted: 0.07 | Np Likeness Score: 0.18 |
1. Shankar SS, Benke SN, Nagendra N, Srivastava PL, Thulasiram HV, Gopi HN.. (2013) Self-assembly to function: design, synthesis, and broad spectrum antimicrobial properties of short hybrid E-vinylogous lipopeptides., 56 (21): [PMID:24117107] [10.1021/jm400884w] |
Source(1):